.png){kind=icon}
.png){kind=icon}
Return
Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM
.png){kind=icon}
OA
AI
B
A
K
Y
F
R
M
W
J
M
M
S
D
L
C
T
G
J
A
J
DOI：10.1016/j.cardfail.2026.05.024.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Atrial fibrillation and/or atrial flutter (AF) was present in 69% of the transthyretin amyloid cardiomyopathy cohort in ATTRibute-CM • Acoramidis reduced mortality or first cardiovascular-related hospitalization, stabilized functional capacity, health status, and biomarkers regardless of baseline AF status, vs. placebo • Acoramidis was associated with fewer new or worsening AF events • Acoramidis led to numerically fewer AF-related cardiovascular hospitalizations
Keywords:
acoramidis
ATTR-CM
ATTRibute-CM
arrhythmia
6MWD
6-minute walk distance
ACM
all-cause mortality
AF
atrial fibrillation and/or atrial flutter
ATTR-CM
transthyretin amyloid cardiomyopathy
CVH
cardiovascular-related hospitalization
eGFR
estimated glomerular filtration rate
HR
hazard ratio
KCCQ-OS
Kansas City Cardiomyopathy Questionnaire Overall Summary
NT-proBNP
N-terminal pro-B-type natriuretic peptide
sTTR
serum transthyretin
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
8.2
Papers:
1.2W
Citations:
7.6K
Organization
No organization information available
Cited Papers